Adults at High Risk for HIV Infection Have Low Rates of Vaccination Against Human Papillomavirus
“ATLANTA – Adults who are at high risk of becoming infected with the human immunodeficiency virus (HIV), which causes...
Search/Filter
Loading...
Maintenance Therapy With Rucaparib Shows Clinical Responses in a Subgroup of Patients With Pancreatic Cancer
“ATLANTA – Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients...
A Genetic Variant Linked to Increased Risk of Stroke in Childhood Cancer Survivors Treated With Cranial Radiation Therapy
ATLANTA – A common single nucleotide polymorphism (SNP) was associated with increased risk for developing stroke in childhood survivors...
Surgery is Associated With Increased Survival for Patients With HER2+ Stage 4 Breast Cancer
Patients without insurance were less likely to receive surgery, increasing disparity in outcomes ATLANTA – Surgery was associated with...
Combination of Virotherapy and Radiotherapy Safe, Shows Early Promise in Vulnerable Patients With Esophageal Cancer
ATLANTA – The experimental oncolytic adenovirus telomelysin (OBP-301) in combination with radiotherapy was safe and showed early clinical efficacy...
Prostate Cancer Incidence and Mortality Have Declined in Most Countries
ATLANTA – Prostate cancer incidence and mortality rates are decreasing or stabilizing in most parts of the world, with...
HDAC Inhibition May Combat Resistance to Anti-PD-1 Therapy in Patients With Melanoma
ATLANTA – A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed...
Next-generation TRK-targeted Therapeutic, LOXO-195, Shows Early Promise Against Tumors with Acquired Resistance to First-generation Therapeutics
ATLANTA – The investigational anticancer therapeutic LOXO-195 (now known as BAY 2731954), which targets a family of proteins called...
Data From Two KEYNOTE Trials Show Pembrolizumab Benefited Patients With Advanced Small Cell Lung Cancer
ATLANTA – The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated,...
Umbralisib Shows Early Promise for Patients with Marginal Zone Lymphoma
ATLANTA – The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients...